Saturday 17 October 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow LIPO
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | — | — |
+8 more TTM periods Free account |
| (361.77%) | (248.35%) | (154.54%) | (198.12%) | ||
| (236.36%) | (186.99%) | (128.38%) | (160.49%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(368.95%) | (204.55%) | (126.51%) | (267.84%) | |
Average Days of Receivables |
— | 32.60 | 60.10 | 57.64 | |
Free Cash Flow per Share |
(1.05) | (1.05) | (1.94) | (3.77) | |
Free Cash Flow |
(4.78) | (4.50) | (3.99) | (3.95) | |
| Other line items | |||||
Cash ROIC |
(142.84%) | (81.52%) | (48.03%) | (96.26%) | |
Accounts Receivable Turnover |
— | 12.17 | 6.73 | 9.17 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 828.18% | 724.00% | 673.60% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 461.74% | 374.40% | 373.55% | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 176.99% | |
Operating CF/Net income |
0.90 | 0.82 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.38 | 0.35 | 0.32 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.11 | 0.25 | 0.51 | |
Operating CF per Share |
(1.05) | (1.05) | (1.94) | (3.77) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates